Long non-coding RNA muskelin 1 antisense RNA as a potential therapeutic target in hepatocellular carcinoma treatment

Xijun Chen; Qing Ye; Zhigao Chen; Qian Lin; Wen Chen; Chengrong Xie; Xiaomin Wang

doi:10.1080/21655979.2022.2074703

Long non-coding RNA muskelin 1 antisense RNA as a potential therapeutic target in hepatocellular carcinoma treatment

Bioengineered. 2022 May;13(5):12237-12247. doi: 10.1080/21655979.2022.2074703.

Authors

Xijun Chen¹, Qing Ye¹, Zhigao Chen¹, Qian Lin¹, Wen Chen¹, Chengrong Xie², Xiaomin Wang^{1

2}

Affiliations

¹ The Third Clinical Medical College, Fujian Medical University, Fuzhou, Fujian, China.
² Xiamen Translational Medical Key Laboratory of Digestive System Tumor, Fujian Provincial Key Laboratory of Chronic Liver Disease and Hepatocellular Carcinoma, Zhongshan Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian, China.

Abstract

Long non-coding RNAs are essential to hepatocellular carcinoma (HCC) development, progression, and incidence of drug resistance. However, the biological significance of long non-coding RNA muskelin 1 antisense RNA (MKLN1-AS) remains poorly characterized. In this study, we observed noticeable increased levels of MKLN1-AS in HCC tissues. This upregulation of MKLN1-AS was clinically associated with vascular invasion and decreased disease-free survival and overall survival of patients with HCC. Functionally, MKLN1-AS-knockdown dramatically suppressed the metastasis and growth of HCC cells in vitro and in vivo. Additionally, the knockdown of MKLN1-AS augmented the pro-apoptosis effect of lenvatinib. Taken together, our findings indicate that MKLN1-AS may be exploited as a potential prognostic predictor and therapeutic target for HCC treatment.

Keywords: Long non-coding RNAs; MKLN1-AS; hepatocellular carcinoma; lenvatinib; prognosis; proliferation; therapeutic target.

MeSH terms

Carcinoma, Hepatocellular* / drug therapy
Carcinoma, Hepatocellular* / genetics
Carcinoma, Hepatocellular* / metabolism
Carcinoma, Hepatocellular* / pathology
Cell Line, Tumor
Cell Movement / drug effects
Cell Movement / genetics
Cell Proliferation / drug effects
Cell Proliferation / genetics
Humans
Liver Neoplasms* / drug therapy
Liver Neoplasms* / genetics
Liver Neoplasms* / metabolism
Liver Neoplasms* / pathology
MicroRNAs* / genetics
Phenylurea Compounds / pharmacology
Quinolines / pharmacology
RNA, Antisense* / genetics
RNA, Antisense* / metabolism
RNA, Long Noncoding* / genetics
RNA, Long Noncoding* / metabolism

Substances

MicroRNAs
Phenylurea Compounds
Quinolines
RNA, Antisense
RNA, Long Noncoding
lenvatinib

Grants and funding

This work was supported by the National Natural Science Foundation of China [NO. 81871961, 81871963, 81802344]; Medical and Health Key project of Xiamen [3502Z20191106].